← Back to Clinical Trials
Recruiting NCT05934149

NCT05934149 Lupus Landmark Study: A Prospective Registry and Biorepository

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05934149
Status Recruiting
Phase
Sponsor Lupus Research Alliance
Condition Systemic Lupus Erythematosus (SLE)
Study Type OBSERVATIONAL
Enrollment 3,500 participants
Start Date 2023-06-28
Primary Completion 2035-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 110 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,500 participants in total. It began in 2023-06-28 with a primary completion date of 2035-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

Eligibility Criteria

Inclusion Criteria: * Able to understand and comply with study procedures and voluntarily sign a written informed consent document * Age 18 years or older at the time of enrollment * Fulfill criteria for SLE based on one or more of the following classifications systems: Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria; European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical assessment. Exclusion Criteria: * Not able to obtain consent * Not able to meet protocol visit requirements * Pregnant at the time of enrollment

Contact & Investigator

Central Contact

Lupus Nexus Director

✉ lupusnexus@lupusresearch.org

📞 646-884-6084

Principal Investigator

Sam Lim, MD, MPH

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT05934149 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Systemic Lupus Erythematosus (SLE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05934149 currently recruiting?

Yes, NCT05934149 is actively recruiting participants. Contact the research team at lupusnexus@lupusresearch.org for enrollment information.

Where is the NCT05934149 trial being conducted?

This trial is being conducted at Birmingham, United States, Tucson, United States, Beverly Hills, United States, Los Angeles, United States and 11 additional locations.

Who is sponsoring the NCT05934149 clinical trial?

NCT05934149 is sponsored by Lupus Research Alliance. The principal investigator is Sam Lim, MD, MPH at Emory University. The trial plans to enroll 3,500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology